<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288232</url>
  </required_header>
  <id_info>
    <org_study_id>17683</org_study_id>
    <nct_id>NCT04288232</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan</brief_title>
  <official_title>A Multicenter, Open-label, Prospective, Interventional Study to Assess the Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IIIb, multicenter, open-label, prospective, interventional study to assess the
      potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five
      monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as
      BCVA assessed at Week 52.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of best corrected visual acuity (BCVA) from baseline to week 52</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>BCVA is measured by ETDRS chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in central subfoveal thickness (CST) from baseline to week 52.</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Central subfoveal thickness (CST) as assessed by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/medium number of injection from baseline to week 52</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Mean/medium number of intravitreal aflibercept injection from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained &gt; 15 ETDRS letters from baseline to week 52</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>BCVA is measured by ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with &gt; 2-step improvement in DRSS from baseline to week 52</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>DR level as assessed by diabetic retinopathy severity score (DRSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects demonstrating retina dry at week 20 and week 52</measure>
    <time_frame>week 20 and week 52</time_frame>
    <description>Retina dry as assessed by OCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Center-involved Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Intravitreal aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept Injection [Eylea]</intervention_name>
    <description>Intravitreal aflibercept Injection 2.0mg/0.05 ml</description>
    <arm_group_label>Intravitreal aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 20 years old with type 1 or 2 diabetes mellitus

          -  Subjects with DME secondary to diabetes mellitus involving the center of the macula
             (defined as the area of the center subfield of optical coherence tomography [OCT]) in
             the study eye

          -  Retinal thickness as assessed by OCT above (&gt;) 300 um in the study eye

          -  BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye

          -  Would be able to comply with clinic visits and study-related procedures

          -  Would be able to provide a signed informed consent form (ICF)

        Exclusion Criteria:

          1. Ocular conditions with a poorer prognosis in the fellow eye than in the study eye

          2. History of vitreoretinal surgery and/or including scleral buckling in the study eye

          3. Laser photocoagulation (pan-retinal or macular) in the study eye within 90 days of Day
             1

          4. Against the background of a relevant number of previous macular laser treatments the
             investigator's point of view was that the subjects had no potential to benefit from
             laser treatments (e.g., if too many laser treatments were applied in the past)

          5. Previous use of intraocular or periocular corticosteroids in the study eye within 120
             days of Day 1

          6. Previous treatment with anti-angiogenic drugs in either eye (pegaptanib sodium,
             bevacizumab, ranibizumab etc.) within 90 days of Day 1

          7. High risk proliferative diabetic retinopathy (PDR) in the study eye upon physician's
             discretion

             High risk = the presence of any of the following:

               -  Vitreous hemorrhage

               -  New vessels on the disk &gt;1/3 disk diameter

               -  New vessels elsewhere &gt;1/2 disk diameter

          8. History of idiopathic or autoimmune uveitis in the study eye

          9. Cataract surgery within 90 days before Day 1 in the study eye

         10. Aphakia in the study eye

         11. Yttrium-aluminium-garnet (YAG) capsulotomy in the study eye within 30 days before Day
             1

         12. Any other intraocular surgery within 90 days of Day 1 in the study eye

         13. Vitreomacular traction or epiretinal membrane in the study eye evident
             biomicroscopically or on OCT that is thought to affect central vision

         14. Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment
             in the study eye

         15. Pre-retinal fibrosis involving the macula in the study eye

         16. Structural damage to the center of the macula in the study eye that was likely to
             preclude improvement in BCVA following the resolution of macular edema including
             atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant
             macular ischemia or organized hard exudates

         17. Ocular inflammation including trace or above in the study eye

         18. Evidence of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either
             eye

         19. Filtration surgery for glaucoma in the past or likely to be needed in the future on
             the study eye

         20. Intraocular pressure (IOP) ≥ 25 mmHg in the study eye

         21. High myopia (≤ -6.0 diopters or axial length of ≥26.5 mm) prior to any possible
             refractive or cataract surgery

         22. Concurrent disease in the study eye, other than DME, that could compromise VA, require
             medical or surgical intervention during the study period, or could confound
             interpretation of the results (including retinal vascular occlusion, retinal
             detachment, macular hole, or choroidal neovascularization of any cause)

         23. Only 1 functional eye even if that eye was otherwise eligible for the study

         24. Ocular media of insufficient quality to obtain fundus and OCT images

         25. Current treatment for a serious systemic infection

         26. Administration of systemic anti-angiogenic agents within 180 days before Day 1

         27. Uncontrolled diabetes mellitus, as defined by Hemoglobin A1c; (glycosylated
             hemoglobin) (HbA1c)&gt;10%.

         28. Uncontrolled blood pressure (defined as systolic &gt;160 mmHg or diastolic &gt;95 mmHg while
             subject was sitting)

         29. History of either cerebral vascular accident and/or myocardial infarction within 180
             days prior to Day 1

         30. Renal failure requiring dialysis or renal transplant

         31. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug, might affect interpretation of the
             results of the study, or rendered the subject at high risk for treatment complications

         32. Pregnant or breast-feeding women

         33. Sexually active men or women of childbearing potential who were unwilling to practice
             adequate contraception during the study were excluded (adequate contraceptive measures
             include stable use of oral contraceptives or other prescription pharmaceutical
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or
             jelly or diaphragm plus contraceptive sponge, foam, or jelly).

         34. Allergy to fluorescein

         35. Participation in an investigational study within 30 days prior to screening visit that
             involved treatment with any drug (excluding vitamins and minerals) or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Jen Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Taipei Veterans General Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984 Apr;102(4):527-32.</citation>
    <PMID>6367725</PMID>
  </reference>
  <reference>
    <citation>Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994 Jun;101(6):1061-70.</citation>
    <PMID>8008348</PMID>
  </reference>
  <reference>
    <citation>Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998 Jun;105(6):998-1003.</citation>
    <PMID>9627648</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, Klein R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010 Aug 11;304(6):649-56. doi: 10.1001/jama.2010.1111.</citation>
    <PMID>20699456</PMID>
  </reference>
  <reference>
    <citation>Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010 Mar 25;362(12):1090-101. doi: 10.1056/NEJMoa0908292.</citation>
    <PMID>20335585</PMID>
  </reference>
  <reference>
    <citation>Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, Sun LP, Friedman DS, Wang NL, Wong TY. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009 Mar;116(3):461-7. doi: 10.1016/j.ophtha.2008.10.003. Epub 2009 Jan 24.</citation>
    <PMID>19168222</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997 Feb;18(1):4-25. Review.</citation>
    <PMID>9034784</PMID>
  </reference>
  <reference>
    <citation>Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000 Dec;11(6):617-24. Review.</citation>
    <PMID>11102799</PMID>
  </reference>
  <reference>
    <citation>Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006 Dec;142(6):961-9. Epub 2006 Aug 2.</citation>
    <PMID>17046701</PMID>
  </reference>
  <reference>
    <citation>Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001. Review.</citation>
    <PMID>19171208</PMID>
  </reference>
  <reference>
    <citation>Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005656. doi: 10.1002/14651858.CD005656.pub2. Review.</citation>
    <PMID>18254088</PMID>
  </reference>
  <reference>
    <citation>El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res. 2010 Nov;29(6):443-65. doi: 10.1016/j.preteyeres.2010.04.001. Epub 2010 Apr 14. Review.</citation>
    <PMID>20398784</PMID>
  </reference>
  <reference>
    <citation>Angelousi A, Larger E. Anaemia, a common but often unrecognized risk in diabetic patients: a review. Diabetes Metab. 2015 Feb;41(1):18-27. doi: 10.1016/j.diabet.2014.06.001. Epub 2014 Jul 17. Review.</citation>
    <PMID>25043174</PMID>
  </reference>
  <reference>
    <citation>Buyukkaya E, Karakas MF, Karakas E, Akçay AB, Tanboga IH, Kurt M, Sen N. Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost. 2014 Mar;20(2):159-63. doi: 10.1177/1076029612459675. Epub 2012 Sep 18.</citation>
    <PMID>22992349</PMID>
  </reference>
  <reference>
    <citation>Sefil F, Ulutas KT, Dokuyucu R, Sumbul AT, Yengil E, Yagiz AE, Yula E, Ustun I, Gokce C. Investigation of neutrophil lymphocyte ratio and blood glucose regulation in patients with type 2 diabetes mellitus. J Int Med Res. 2014 Apr;42(2):581-8. doi: 10.1177/0300060513516944. Epub 2014 Feb 24.</citation>
    <PMID>24567354</PMID>
  </reference>
  <results_reference>
    <citation>Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009 Aug;116(8):1488-97, 1497.e1. doi: 10.1016/j.ophtha.2009.03.016. Epub 2009 Jul 9.</citation>
    <PMID>19545900</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.</citation>
    <PMID>20427088</PMID>
  </results_reference>
  <results_reference>
    <citation>Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012 Aug;119(8):1658-65. doi: 10.1016/j.ophtha.2012.02.010. Epub 2012 Apr 24.</citation>
    <PMID>22537617</PMID>
  </results_reference>
  <results_reference>
    <citation>Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.</citation>
    <PMID>25012934</PMID>
  </results_reference>
  <results_reference>
    <citation>Terasaki H, Shiraki K, Ohji M, Metzig C, Schmelter T, Zeitz O, Sowade O, Kobayashi M, Vitti R, Berliner A, Shiraga F. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN. Retina. 2019 May;39(5):938-947. doi: 10.1097/IAE.0000000000002100.</citation>
    <PMID>29470308</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 9, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-VEGF</keyword>
  <keyword>intravitreal aflibercept</keyword>
  <keyword>diabetic macular edema</keyword>
  <keyword>Treat-and-Extend regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

